Browsing by Author Ruiz Borrego, Manuel
Showing results 1 to 6 of 6
| Issue Date | Title | Author(s) |
|---|---|---|
| 17-Jun-2025 | Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial | Llombart Cussac, Antonio; Pérez García, José Manuel; Bellet Ezquerra, Meritxell; Dalenc, Florence; Gil Gil, Miguel; Ruiz Borrego, Manuel; Gavilá, Joaquín; Schmid, Peter; Zamora, Pilar; Wheatley, Duncan; Martínez de Dueñas, Eduardo; Amillano, Kepa; Di Cosimo, Serena; Antón, Antonio; Cottu, Paul-Henri; Shimizu, Eileen; Fernandez Pinto, Melissa; Sampayo Cordero, Miguel; Cortés, Javier |
| 1-Oct-2021 | Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study | Kahan, Zsuzsanna; Gil Gil, Miguel; Ruiz Borrego, Manuel; Carrasco, Eva; Ciruelos, Eva; Muñoz Mateu, Montserrat; Bermejo, Begoña; Margeli, Mireia; Antón, Antonio; Casas, Maribel; Csöszi, Tibor; Murillo, Laura; Morales, Serafín; Calvo, Lourdes; Lang, Istvan; Alba, Emilio; Haba Rodriguez, Juan de la; Ramos, Manuel; Álvarez López, Isabel; Gal Yam, Einav; García Palomo, Andrés; Alvarez, Elena; González Santiago, Santiago; Rodríguez, César A.; Servitja, Sonia; Corsaro, Massimo; Rodrigálvarez, Graciela; Zielinski, Christoph; Martín, Miguel |
| 1-Aug-2024 | Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer | Di Cosimo, Serena; Pérez García, José Manuel; Bellet Ezquerra, Meritxell; Dalenc, Florence; Gil Gil, Miguel; Ruiz Borrego, Manuel; Gavilá, Joaquín; Aguirre, Elena; Schmid, Peter; Marmé, Frederik; Gligorov, Joseph; Schneeweiss, Andreas; Albanell, Joan; Zamora, Pilar; Wheatley, Duncan; Martínez De Dueñas, Eduardo; Amillano, Kepa; Shimizu, Eileen; Sampayo Cordero, Miguel; Cortés, Javier; Llombart Cussac, Antonio |
| 1-Apr-2021 | Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL | Martin, M.; Zielinski, C.; Ruiz Borrego, Manuel; Carrasco, E.; Turner, N.; Ciruelos, Eva; Muñoz Mateu, Montserrat; Bermejo de las Heras, Begoña; Margelí Vila, Mireia; Anton, A.; Kahan, Z.; Csöszi, T.; Casas, M. I.; Murillo, L.; Morales, S.; Alba, Emilio; Gal Yam, E.; Guerrero Zotano, A.; Calvo, L.; Haba Rodríguez, J. de la; Ramos, M.; Álvarez López, Isabel; García Palomo, Andrés; Huang Bartlett, C.; Koehler, M.; Caballero, R.; Corsaro, M.; Huang, X.; García Sáenz, José Ángel; Chacón, José Ignacio; Swift, C.; Thallinger, C.; Gil Gil, Miguel |
| 1-Jul-2025 | Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor–Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial | Agrawal, Yash N.; Fernández Martínez, Aranzazu; Gil Gil, Miguel; Zielinski, Christoph; Ruiz Borrego, Manuel; Ciruelos, Eva; Muñoz Mateu, Montserrat; Margelí Vila, Mireia; Bermejo de las Heras, Begoña; Anton Torres, Antonio; Kahan, Zsuzsanna; Csöszi, Tibor; Alonso Romero, José Luis; García Saenz, José Ángel; Sánchez Rovira, Pedro; Álvarez, Elena; Chacón, José Ignacio; González Santiago, Santiago; Rodríguez Sánchez, César A.; Servitja, Sonia; Pfefferle, Adam D.; Herranz, Jesús; Liu, Yuan; Carey, Lisa A.; Romero Camarero, Isabel; Caballero, Rosalía; Guerrero Zotano, Ángel; Perou, Charles M.; Martín, Miguel |
| 27-Oct-2022 | Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study | Pérez García, José Manuel; Gebhart, Geraldine; Ruiz Borrego, Manuel; Schmid, Peter; Marmé, Frederik; Prat Aparicio, Aleix; Dalenc, Florence; Kerrou, Khaldoun; Colleoni, Marco; Braga, Sofía; Malfettone, Andrea; Sampayo Cordero, Miguel; Cortes, Javier; Llombart Cussac, Antonio |